PRKAA1 and prostate carcinoma: The activation of AMPK was previously shown to trigger mitochondrial biogenesis and OXPHOS, causing anti-Warburg [23] and anti-proliferative [21] effects in several types of cancer [24], such as leukemia [39], breast cancer [40], pancreatic cancer [41], hepatocellular carcinoma [42], and prostate cancer [43].